DBVT Key Statistics, Chart & Performance
The current stock price of DBVT is 17.01 USD. In the past month the price decreased by -14.95%. In the past year, price increased by 242.25%.
DBVT Latest News, Press Relases and Analysis
DBVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About DBVT
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 109
Phone: 33155427878
DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ
Can you describe the business of DBV TECHNOLOGIES SA-SPON ADR?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is the current price of DBVT stock?
The current stock price of DBVT is 17.01 USD. The price increased by 0.06% in the last trading session.
What is the dividend status of DBV TECHNOLOGIES SA-SPON ADR?
DBVT does not pay a dividend.
How is the ChartMill rating for DBV TECHNOLOGIES SA-SPON ADR?
DBVT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for DBVT stock?
8 analysts have analysed DBVT and the average price target is 24.92 USD. This implies a price increase of 46.5% is expected in the next year compared to the current price of 17.01.
How many employees does DBV TECHNOLOGIES SA-SPON ADR have?
DBV TECHNOLOGIES SA-SPON ADR (DBVT) currently has 109 employees.
What is DBV TECHNOLOGIES SA-SPON ADR worth?
DBV TECHNOLOGIES SA-SPON ADR (DBVT) has a market capitalization of 611.48M USD. This makes DBVT a Small Cap stock.
DBVT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DBVT. When comparing the yearly performance of all stocks, DBVT is one of the better performing stocks in the market, outperforming 98.07% of all stocks.
DBVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBVT. DBVT has a bad profitability rating. Also its financial health evaluation is rather negative.
DBVT Financial Highlights
Over the last trailing twelve months DBVT reported a non-GAAP Earnings per Share(EPS) of -2.51. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.01% | ||
| ROE | -143.02% | ||
| Debt/Equity | 0.08 |
DBVT Forecast & Estimates
8 analysts have analysed DBVT and the average price target is 24.92 USD. This implies a price increase of 46.5% is expected in the next year compared to the current price of 17.01.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBVT